Marilyn J Manco-Johnson
Overview
Explore the profile of Marilyn J Manco-Johnson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
2122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goldenberg N, Schulman S, Kittelson J, Abshire T, Casella J, Dale R, et al.
J Thromb Haemost
. 2024 Oct;
23(2):651-656.
PMID: 39461724
Background: The Multicenter Evaluation of the Duration of Therapy for Thrombosis in Children multinational, randomized clinical trial revealed noninferiority of a 6-week vs 3-month duration of anticoagulation for the treatment...
2.
Mah J, Robertson C, Mah N, Roybal J, Thornhill D, Funk S, et al.
Clin Biomech (Bristol)
. 2024 Oct;
120:106361.
PMID: 39461281
Background: Persons with hemophilia experience joint bleeding that can lead to debilitating arthropathy, most commonly seen in ankles, knees, and elbows. Arthropathy can hinder participation in daily and athletic activities....
3.
Manco-Johnson M, Annam A, Schardt T
Tech Vasc Interv Radiol
. 2024 Aug;
27(2):100958.
PMID: 39168548
The use of antithrombotic agents is increasing in infants, children and adolescents. The more recent routine inclusion of children in FDA-monitored clinical trials has propelled the rapid accumulation of safety...
4.
5.
Casini A, Abdul Kadir R, Abdelwahab M, Manco-Johnson M, Raut S, Ross C, et al.
J Thromb Haemost
. 2024 Jan;
22(5):1516-1521.
PMID: 38266678
Congenital fibrinogen disorders (CFDs) are a heterogeneous group of rare congenital quantitative and/or qualitative fibrinogen deficiencies. The spectrum of molecular anomalies is broad, leading to several subtypes of fibrinogen disorders...
6.
Warren B, Moyer G, Manco-Johnson M
Semin Thromb Hemost
. 2023 Feb;
49(4):319-329.
PMID: 36750218
The hemostasis system is composed of procoagulant, anticoagulant, and fibrinolytic proteins that interact with endothelial and blood cells and with each other in a complex system of checks and balances...
7.
Goldenberg N, Kittelson J, Abshire T, Bonaca M, Casella J, Dale R, et al.
JAMA
. 2022 Jan;
327(2):129-137.
PMID: 35015038
Importance: Among patients younger than 21 years of age, the optimal duration of anticoagulant therapy for venous thromboembolism is unknown. Objective: To test the hypothesis that a 6-week duration of...
8.
Manco-Johnson M, Warren B, Buckner T, Funk S, Wang M
Haemophilia
. 2021 Jan;
27 Suppl 3:87-95.
PMID: 33398908
Options for management of haemophilia are increasing rapidly with completely novel therapeutic approaches that cannot be compared using traditional factor assays. In addition, as prophylaxis regimens have improved, bleeding rates...
9.
Maher K, Gibson E, Warren B, Funk S, Shearer R, Buckner T, et al.
Pediatr Blood Cancer
. 2020 Sep;
68(1):e28577.
PMID: 32881253
No abstract available.
10.
Slatnick L, Thornhill D, Davies S, Ford J, Scott H, Manco-Johnson M, et al.
J Pediatr
. 2020 Jun;
225:198-206.e2.
PMID: 32553867
Objective: To evaluate the impact of early disseminated intravascular coagulation (DIC) on illness severity in children using a database of emergency department ED encounters for children with suspected sepsis, in...